← Back to Search

Other

CX1739 - 300 mg for Respiratory Depression

Phase 2
Waitlist Available
Research Sponsored by RespireRx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up sequence #1 - 30 minutes
Awards & highlights

Study Summary

The study is an investigation to assess the capacity of ascending doses of CX1739 to antagonize the respiratory depressive effect of remifentanil. The study will also investigate whether ascending doses of CX1739 reduce the analgesic effect of remifentanil or alter the BIS measure of sedation and will evaluate the safety of CX1739 when used in conjunction with remifentanil.

Eligible Conditions
  • Respiratory Depression

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~sequence #1 - 30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and sequence #1 - 30 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Respiratory depression
Secondary outcome measures
Change in pupil size
Maintenance of sedation
Pain
+1 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: CX1739 - 900 mgExperimental Treatment1 Intervention
Study drug - high dose
Group II: CX1739 - 600 mgExperimental Treatment1 Intervention
Study drug - mid Dose
Group III: CX1739 - 300 mgExperimental Treatment1 Intervention
Study Drug - low dose
Group IV: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

RespireRxLead Sponsor
4 Previous Clinical Trials
348 Total Patients Enrolled
Duke UniversityOTHER
2,360 Previous Clinical Trials
3,420,312 Total Patients Enrolled
2 Trials studying Respiratory Depression
84 Patients Enrolled for Respiratory Depression
Richard PurcellStudy DirectorRespireRx Pharmaceuticals

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia
2016. "Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02735629.
All > Opiate Addiction
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top